

Nationally Contracted Products FAQ

Barrier Film



1. What is the aim of NCP and how are the products chosen?

A

Skin Barrier Films are part of the General Wound Care Framework Agreement of which Skin Protectants forms the third largest area. The procurement strategy for this category was developed following the publication of the CET publication for Skin Barrier Films. The CET report can be found [here](#). Reference to this report informed the procurement strategy together with wide customer and stakeholder engagement for this category of products.

The intelligence gained from the CET national engagement events and the results of the product range evaluation formed the foundation of the evidence required to ensure the products listed remain fit for purpose, safe, and value for money.

Additional engagement nationally with the NHS and Suppliers was necessary to be able to determine and reflect NHS informed criteria and evaluation methods, where possible in the existing specification and subsequently to be able to meet SCCLs Clinical and Product Assurance framework.

2. How does this align with the National Wound Care Strategy Programme (NWCSP)?

A

The CTSP are currently working towards aligning all their Wound Care strategies with the work of the NWCSP. This strategy outcome preceded the specification work that is currently being undertaken nationally however this range of products will be included within the scope of the national work for the next framework renewal.

3. Which products have been included in this NCP?

A

- Barrier Film Foam Applicator 1ml
- Barrier Film Foam Applicator 3ml
- Barrier Film Spray 28ml – 30ml



4. Will you still have stock of current products available when the Skin Barrier Films Nationally Contracted Products (NCP) is launched on 12 August 2019?

A

Existing products will be available whilst stock lasts; any outstanding stock will still be available until stock has been depleted. When stock has been depleted you will only be able to order the NCP products.

5. Are the NPC's changing?

A

NPCs will not change.

6. Which products have been included in this NCP?

A

Medicareplus International Limited

<u>NPC</u>	<u>MPC</u>	<u>Description</u>
ELY532	MB61076	Barrier film foam applicator no sting sterile 1ml
ELY533	MB61090	Barrier film foam applicator no sting sterile 3ml
ELY562	MB60796	Barrier film spray no sting sterile 30ml pump action

3M United Kingdom PLC

<u>NPC</u>	<u>MPC</u>	<u>Description</u>
ELY038	3343E	Barrier film foam applicator no sting sterile 1ml
ELY039	3345E	Barrier film foam applicator no sting sterile 3ml
ELY040	3346E	Barrier film spray no sting sterile 28ml pump action

7. Do I need to make any system changes to update standing orders and favourite lists?

A

Updates to favourites lists, standing orders and eDC requirements should be carried out by the trust in line with your normal procedures.

8. Are samples available?

A

Yes, samples will be available. These can be ordered in the usual way or by contacting the Supplier directly. Further information can be found [here](#).



9. What supply chain resilience can you guarantee if one of the suppliers has a supply issue?

A

The NCP procurement process includes a range of due diligence activities to ensure there is supply chain resilience and sustainable continuity of supply to NHS customers. Both NHS Supply Chain and the suppliers have increased stock holding. In the event of any supply issue, direct alternatives will be supplied, at point of order, at no extra cost to the trust.

10. What will happen if I choose to order directly from the supplier?

A

NHS Improvement has been engaging with trusts directly over the expectation that they will support this national programme. Monitoring of trust spend will be in place through the national price benchmarking tool. Where a trust is not participating in the national savings programme, their actions will have to be justified.

11. Is there a risk that existing products will be delisted too soon?

A

Delisted stock lines will be listed as “available whilst stock lasts”, any outstanding stock will still be available until stock has been depleted. You can continue to utilise your stocks of the current lines until these have also been depleted.

12. What impact will this have on any customer commitment discounts and retrospective rebates?

A

In line with the recommendations of the Carter report there is a national strategy to deliver transparent pricing. Therefore, there are:

- No commitment discounts or retrospective rebates
- No local commitment discounts or retrospective rebates
- No facilitated commitment discount schemes.

For any trusts currently signed up to the existing Medicareplus NPM for Skin Protectants, this will cease on 12 August 2019 as the offering created through this opportunity far outweighs the benefits of the existing NPM agreement.



13. What do trusts do should there be any clinical or other issue with the product allocated to their trust?

A

In the first instance please contact your Customer Services Advisor.

14. What if my trust is currently buying a similar product at a cheaper price?

A

Benchmarking prices using NHSI's national price benchmarking tool PPIB, will highlight where a trust may be paying a cheaper local price. We would ask you to please notify NHSI and your Account Manager of these instances so that the situation can be addressed.

15. What support will be available to trusts during the implementation and conversion period to minimise the impact on current resources?

A

Support will be available from your [Account Manager](#). The successful suppliers on the NCP programme can provide you with product training and information if required.

Information is also available via our [Clinical Nurse Advisors](#).

16. Where can I get more detailed information?

A

Please visit www.supplychain.nhs.uk/ncp for the latest information about the NCP programme.

You can also contact your Account Manager or Customer Services Advisor.

